Premium
The association of Vitamin D levels to advanced liver fibrosis and response to hepatitis C therapy
Author(s) -
Elhag mashair Khougali Abdelrahman,
Deiab shihab,
Hussain Nadia,
Aziz Rasha Khougali Abdelrahman
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.571.3
Subject(s) - ribavirin , medicine , confidence interval , odds ratio , gastroenterology , vitamin d and neurology , pegylated interferon , hepatitis c , cochrane library , chronic hepatitis , fibrosis , immunology , virus
The importance of vitamin D in many diseases has come to light recently. In the Middle East, there is a prevalence of low vitamin D levels. Evidence linking vitamin D to the parthogenesis of chronic hepatitis C is present. The aim of this study is to analyze the relationship of vitamin D levels with advanced liver fibrosis (ALF) CHC treatment‐naive patients and sustained virology response (SVR) in CHC patients on PEGylated interferon alpha plus ribavirin (pegIFNa/ribavirin) therapy. Materials and methods A meta‐analysis of eligible studies published from 1999 to 2014 was conducted. Databases such as PubMed, SCOPUS, Web of Science, and the Cochrane Library were used. Studies assessed included data assessment between plasma/serum vitamin D levels and its relation to ALF and/or SVR. Pooled odds ratios (ORs) were estimated by either fixed or random effects models. Eighteen studies were selected from the literature search, seven for ALF (1,099 patients) and 11 for SVR (2,580 patients). For liver fibrosis, low vitamin D status was related to a diagnosis of ALF, with the cutoffs of 10 ng/mL (OR=2.37, 95% confidence interval, [CI] = 1.20, 4.72) and 30 ng/ml (OR=2.22, 95% CI = 0.99, 3.97) being significant, and a near‐significance for 20 ng/ml. Results Regarding SVR, there was a significant heterogeneity among studies (P< 0.001). A significant association with SVR for a vitamin D cutoff of 20 ng/mL (OR=0.53, 95% CI=0.31, 0.91) was present. When meta‐analysis was performed excluding the outliers, significant pooled ORs were found for all patients (10 ng/mL [OR=0.48, 95% CI=0.34, 0.67] and 20 ng/mL [OR=0.58, 95% CI=0.45, 0.76]) and GT1/4 patients (10 ng/mL [OR=0.53, 95% CI=0.34, 0.81] and 20 ng/mL [OR=0.54, 95% CI=0.39, 0.74]). Conclusion Low vitamin D status in CHC patients is associated with a higher likelihood of having ALF and lower odds of achieving SVR following pegIFN/ribavirin therapy. Also vitamin D supplementation could improve the SVR rate in patients treated with pegIFN/ribavirin. Support or Funding Information This work was supported and funded by Ras Alkhaimah medical and health science university This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .